Literature DB >> 6488332

Protein phosphorylation in anti-actin IgG and [(IgG)2protein A]2 complex-stimulated L cells.

W T Shearer, E B Gilliam, J E McClure.   

Abstract

Phosphorylation of cellular proteins was stimulated in a dose-dependent manner by the surface binding of IgG antibodies to antigens on L cells. Most prominent among the phosphorylated cellular proteins were Mr = 115,000, 93,000, 58,000, 38,000, and 33,000 proteins. Stimulation of protein phosphorylation was maximal at 48 hr of incubation and was preceeded by maximal stimulated uridine incorporation into RNA (0-24 hr) and thymidine incorporation into DNA (24-48 hr), and followed by maximal stimulated cell proliferation occurring at 72 hr (P less than 0.001 for all differences). Modification of the ligand IgG molecule by formation of complexes with protein A (PA) altered the stimulation patterns of protein phosphorylation: [(IgG)2(PA)]2, Mr = 716,000, enhanced and (IgG)(PA), Mr = 200,000, inhibited phosphorylation. The nature of the cell surface antigen(s) was partially clarified by the demonstration that affinity-purified antibodies to cytoskeletal proteins (principally a surface actin molecule) accounted for a significant part of the stimulation effect. Thus, perturbation of the L-cell membrane by certain molecular forms of anti-actin IgG antibody produces a transmembrane signal resulting in an orderly series of metabolic events including enhanced protein phosphorylation at 48 hr occurring just prior to enhanced cell growth.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488332     DOI: 10.1016/0008-8749(84)90197-7

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  1 in total

1.  Cyclic AMP and theophylline enhance DNA synthesis in L cells stimulated with anti-actin IgG and [(IgG)2 protein A]2 complex by recruiting cells into S-phase.

Authors:  W T Shearer; R G Ulrich; J E McClure; C G Green; E B Gilliam; C Das; J J Langone
Journal:  Mol Cell Biochem       Date:  1985-07       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.